97 related articles for article (PubMed ID: 26458879)
1. Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition.
Bonner JA; Trummell HQ; Bonner AB; Willey CD; Bredel M; Yang ES
BMC Cancer; 2015 Oct; 15():673. PubMed ID: 26458879
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.
Bonner JA; Yang ES; Trummell HQ; Nowsheen S; Willey CD; Raisch KP
Radiother Oncol; 2011 Jun; 99(3):339-43. PubMed ID: 21704410
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.
Hu Y; Dong XZ; Liu X; Liu P; Chen YB
Mol Pharm; 2016 Feb; 13(2):689-97. PubMed ID: 26685983
[TBL] [Abstract][Full Text] [Related]
4. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor-induced cell death and radiosensitization in epidermal growth factor receptor-overexpressing cancer cell lines.
Kim K; Wu HG; Jeon SR
Anticancer Res; 2015 Jan; 35(1):245-53. PubMed ID: 25550557
[TBL] [Abstract][Full Text] [Related]
6. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
7. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.
Heravi M; Rachid Z; Goudarzi A; Schlisser A; Jean-Claude BJ; Radzioch D; Muanza TM
Anticancer Drugs; 2009 Sep; 20(8):659-67. PubMed ID: 19581798
[TBL] [Abstract][Full Text] [Related]
8. Targeting of the EGFR/β1 integrin connecting proteins PINCH1 and Nck2 radiosensitizes three-dimensional SCC cell cultures.
Rossow L; Eke I; Dickreuter E; Cordes N
Oncol Rep; 2015 Jul; 34(1):469-76. PubMed ID: 26004008
[TBL] [Abstract][Full Text] [Related]
9. EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.
Poschau M; Dickreuter E; Singh-Müller J; Zscheppang K; Eke I; Liersch T; Cordes N
Radiother Oncol; 2015 Sep; 116(3):510-6. PubMed ID: 26096850
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.
Taverna P; Hwang HS; Schupp JE; Radivoyevitch T; Session NN; Reddy G; Zarling DA; Kinsella TJ
Cancer Res; 2003 Feb; 63(4):838-46. PubMed ID: 12591735
[TBL] [Abstract][Full Text] [Related]
13. Equol as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines.
Taghizadeh B; Ghavami L; Nikoofar A; Goliaei B
Breast Cancer; 2015 Jul; 22(4):382-90. PubMed ID: 24014377
[TBL] [Abstract][Full Text] [Related]
14. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.
Dittmann KH; Mayer C; Ohneseit PA; Raju U; Andratschke NH; Milas L; Rodemann HP
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):203-12. PubMed ID: 17996386
[TBL] [Abstract][Full Text] [Related]
16. The role of G2-block abrogation, DNA double-strand break repair and apoptosis in the radiosensitization of melanoma and squamous cell carcinoma cell lines by pentoxifylline.
Theron T; Binder A; Verheye-Dua F; Böhm L
Int J Radiat Biol; 2000 Sep; 76(9):1197-208. PubMed ID: 10993631
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic and radio-sensitizing effects of polyphenolic acetates in a human glioma cell line (BMG-1).
Verma A; Venkateswaran K; Farooque A; Bhatt AN; Kalra N; Arya A; Dhawan A; Arya MB; Raj HG; Prasad AK; Parmar VS; Dwarakanath BS
Curr Pharm Des; 2014; 20(7):1161-9. PubMed ID: 24552186
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity.
Dittmann K; Mayer C; Rodemann HP
Radiother Oncol; 2005 Aug; 76(2):157-61. PubMed ID: 16024112
[TBL] [Abstract][Full Text] [Related]
19. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells.
Eke I; Schneider L; Förster C; Zips D; Kunz-Schughart LA; Cordes N
Cancer Res; 2013 Jan; 73(1):297-306. PubMed ID: 23074283
[TBL] [Abstract][Full Text] [Related]
20. The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines.
Yuan HH; Han Y; Bian WX; Liu L; Bai YX
Pathology; 2012 Oct; 44(6):547-51. PubMed ID: 22935976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
